The Effects of Mitomycin C on Trabeculectomy.
- Author:
Soon Jae HONG
1
;
Sung Chur MOON
;
Kyung Won YOO
;
Sae Heun RHO
Author Information
1. Department of Ophthalmology, College of Medicine, Dong A University, Pusan, Korea.
- Publication Type:Original Article
- Keywords:
Intraocular pressure (IOP);
Mitomycin C (MMC);
Poor prognostic glaucoma;
Trabeculectomy
- MeSH:
Anterior Chamber;
Blister;
Cataract;
Choroid;
Fibroblasts;
Fibrosis;
Filtering Surgery;
Glaucoma;
Humans;
Hyphema;
Intraocular Pressure;
Iridectomy;
Mitomycin*;
Postoperative Complications;
RNA;
Rupture;
Trabeculectomy*;
Wounds and Injuries
- From:Journal of the Korean Ophthalmological Society
1996;37(9):1570-1575
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Mitomycin C (MMC) is an antimetabolite, antibiotic which prevents the proliferation of fibroblast and fibrosis by inhibition of DNA-dependent RNA synthesis. It has been used to increase the success rate of filtering surgery. We performed trabeculectomy and peripheral iridectomy with 0.4 mg/ml MMC application for 3 minutes in poor prognostic glaucoma patient, 26 eyes of 24 patients from February 1992 to December 1994. The postoperative change of intraocular pressure (IOP) and complications were followed up from 3 to 30 months (mean 12.4 months). The preoperative and postoperative mean IOP after 24 months were 32.3 +/- 11.4 mmHg and 12.7 +/- 3.1 mmHg, respectively. The decrease rate of IOP was 60.7% and the success rate was 71.7%. The postoperative complications were 15 eyes including 5 eyes of shallow anterior chamber, 5 eyes of hyphema, 2 eyes of conjunctival wound leakage, one eye of bleb rupture, one eye of choroidal detachment, and one eye of cataract formation.
